Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment
Abstract
This study, conducted in three separate outpatient health care delivery settings, examined the therapeutic expectations of patients with multiple sclerosis (MS) before they initiated interferon beta-lb therapy, the results of current educational procedures to correct unrealistic expectations, and the relationship between post-education expectations and discontinuing therapy. Ninety-nine consecutive patients were seen in a university based outpatient MS clinic, an academic group practice outpatient MS clinic, or a health maintenance organization outpatient neurology clinic Before the educational sessions, 57% of the patients expressed unrealistically optimistic expectations regarding reduction in attack rate and 34% expressed unrealistically optimistic expectations regarding improvement in functional status. Educational procedures significantly altered unrealistic expectations but the results were sub-optimal since 33% of the patients maintained overly optimistic expectations regarding reduction in attack rate. Post-education unrealistic expectations of improvement in functional status were significantly related to discontinuing therapy within 6 months. Three adverse effects of therapy also were related independently to adherence to treatment depression and flu-like symptoms were related to discontinuing therapy while soreness at injection site was related to continuing therapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Depression is related to neurological changes in the brain due to the demyelination process, treatment adherence, immune functioning, and MS disease exacerbation.
“For example, depression has been found to be related to neurological changes in the brain due to the demyelination process [20], treatment adherence to medical advice and treatments [21], immune functioning [22] and MS disease exacerbation [23].”
Cites
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384 · see citing works
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. Μ., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,446 · see citing works
Self-citationInterferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085 · see citing works
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,964 · see citing works
(1980) · Postgraduate Medical Journal · doi:10.1136/pgmj.56.657.530 · Cited by 1,829 · see citing works
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
Johnson, K., Brooks, B., Cohen, J. A., Ford, C., Goldstein, J., Lisak, R., Myers, L., Panitch, H., Rose, J., Schiffer, R., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,667 · see citing works
Adherence to Medication Regimens: Updating a Complex Medical Issue
O'brien, M. K., Petrie, K., & Raeburn, J. (1992) · Medical Care Review · doi:10.1177/002570879204900403 · Cited by 202 · see citing works
Goodkin, D. E. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91713-2 · Cited by 41 · see citing works
Self-citationInterferon beta treatment for multiple sclerosis: persisting questions
Goodkin, D. E. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600100605 · Cited by 15 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Rae-Grant, A. D., Day, G. S., Marrie, R. A., Rabinstein, A. A., Cree, B., Gronseth, G., Haboubi, M., Halper, J., Hosey, J. P., Jones, D., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005347 · Cited by 596 · see citing works
Devonshire, V. A., Lapierre, Y., Macdonell, R. A. L., Ramo-Tello, C. M., Patti, F., da Fontoura, P. P., Suchet, L., Hyde, R., Balla, I., Frohman, E. M., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03110.x · Cited by 339 · see citing works
Mohr, D. C., Boudewyn, A. C., Goodkin, D. E., Bostrom, A., & Epstein, L. (2001) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.69.6.942 · Cited by 334 · see citing works
Self-citationTreatment of Depression Improves Adherence to Interferon Beta-1b Therapy for Multiple Sclerosis
Mohr, D. C., Goodkin, D., Likosky, W., Gatto, N. M., Baumann, K. A., & Rudick, R. A. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550170015009 · Cited by 306 · see citing works
Self-citationWalther, E. U., & Hohlfeld, R. (1999) · Neurology · doi:10.1212/wnl.53.8.1622 · Cited by 303 · see citing works
Psychological interventions for multiple sclerosis.
Thomas, P. W., Thomas, S., Hillier, C., Galvin, K., & Baker, R. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004431.pub2 · Cited by 271 · see citing works
Mohr, D. C., Likosky, W., Bertagnolli, A., Goodkin, D. E., Wende, J. V. D., Dwyer, P., & Dick, L. P. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.68.2.356 · Cited by 240 · see citing works
Self-citationTremlett, H. L., & Oger, J. J.-F. (2003) · Neurology · doi:10.1212/01.wnl.0000078885.05053.7d · Cited by 208 · see citing works
Mohr, D. C., Likosky, W., Bertagnolli, A., Goodkin, D. E., Van Der Wende, J., Dwyer, P., & Dick, L. P. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.2.356 · Cited by 240 · see citing works
Self-citationRío, J., Porcel, J., Téllez, N., Sánchez-Betancourt, A., Tintoré, M., Arévalo, M. J., Nos, C., & Montalbán, X. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1173oa · Cited by 188 · see citing works
Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence
Patti, F. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s8230 · Cited by 170 · see citing works
Multiple sclerosis beyond EDSS: depression and fatigue.
Ziemssen, T. (2009) · Journal of Neurological Sciences · doi:10.1016/s0022-510x(09)70011-5 · Cited by 168 · see citing works
Mohr, D., Boudewyn, A., Likosky, W., Levine, E. G., & Goodkin, D. E. (2001) · Annals of Behavioral Medicine · doi:10.1207/s15324796abm2302_7 · Cited by 169 · see citing works
Self-citationPsychological aspects of multiple sclerosis
Sá, M. J. (2008) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2007.10.001 · Cited by 155 · see citing works
Heesen, C., Kasper, J., Segal, J., Köpke, S., & Mühlhauser, I. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1112oa · Cited by 154 · see citing works
Treatment of depression in multiple sclerosis: Review and meta-analysis.
Mohr, D. C., & Goodkin, D. E. (1999) · Clinical Psychology: Science and Practice · doi:10.1093/clipsy.6.1.1 · Cited by 155 · see citing works
Self-citationStopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns
O’Rourke, K., & Hutchinson, M. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1131oa · Cited by 135 · see citing works
Depression, coping and level of neurological impairment in multiple sclerosis
Mohr, D. C., Goodkin, D. E., Gatto, N. M., & Wende, J. V. D. (1997) · Multiple Sclerosis Journal · doi:10.1177/135245859700300408 · Cited by 130 · see citing works
Self-citationIdentification of Beck Depression Inventory Items Related to Multiple Sclerosis
Mohr, D. C., Goodkin, D. E., Likosky, W., Beutler, L. E., Gatto, N. M., & Langan, M. K. (1997) · Journal of Behavioral Medicine · doi:10.1023/a:1025573315492 · Cited by 129 · see citing works
Self-citationCognitive–behavioral therapy: what benefits can it offer people with multiple sclerosis?
Dennison, L., & Moss-Morris, R. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.111 · Cited by 124 · see citing works
Multiple sclerosis: Empirical literature for the clinical health psychologist
Mohr, D. C., & Cox, D. (2001) · Journal of Clinical Psychology · doi:10.1002/jclp.1042 · Cited by 176 · see citing works
Self-citationPsychiatric side effects of interferon-β in multiple sclerosis
Goëb, J.-L., EVEN, C., Nicolas, G., Gohier, B., Dubas, F., & Garré, J.-B. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2005.09.013 · Cited by 95 · see citing works
Mohr, D., Goodkin, D. E., Nelson, S., Cox, D., & Weiner, M. (2002) · Psychosomatic Medicine · doi:10.1097/01.psy.0000024238.11538.ec · Cited by 85 · see citing works
Self-citationPatten, S. B., & Metz, L. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700406 · Cited by 83 · see citing works
Tremlett, H. L., van der Mei, I. A. F., Pittas, F., Blizzard, L., Paley, G., Dwyer, T., Taylor, B. V., & Ponsonby, A. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1593 · Cited by 78 · see citing works
Prosser, L. A., Kuntz, K. M., Bar‐Or, A., & Weinstein, M. C. (2004) · Value in Health · doi:10.1111/j.1524-4733.2004.75007.x · Cited by 76 · see citing works
Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la
Mohr, D. C., Likosky, W., Boudewyn, A. C., Marietta, P., Dwyer, P., Wende, J. V. D., & Goodkin, D. E. (1998) · Multiple Sclerosis Journal · doi:10.1177/135245859800400605 · Cited by 75 · see citing works
Self-citationKraus, M. R., Schäfer, A., Csef, H., Faller, H., Mörk, H., & Scheurlen, M. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1011973823032 · Cited by 73 · see citing works
Managing the Adverse Effects of Interferon-?? Therapy in Multiple Sclerosis
Bayas, A., & Rieckmann, P. (2000) · Drug Safety · doi:10.2165/00002018-200022020-00006 · Cited by 71 · see citing works
Multiple sclerosis, disease modifying treatments and depression: a critical methodological review
Feinstein, A. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600509 · Cited by 69 · see citing works
Lugaresi, A. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903134769 · Cited by 68 · see citing works
Giovannoni, G., Барбараш, О. Л., Casset‐Semanaz, F., King, J. O., Metz, L. M., Pardo, G., Simsarian, J., Sørensen, P. S., Stubinski, B., & on behalf of the Rebif® New Formulation Study Group (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508097299 · Cited by 68 · see citing works
Course of Depression During the Initiation of Interferon Beta-1a Treatment for Multiple Sclerosis
Mohr, D. C., Likosky, W., Dwyer, P., Wende, J. V. D., Boudewyn, A. C., & Goodkin, D. (1999) · Archives of Neurology · doi:10.1001/archneur.56.10.1263 · Cited by 68 · see citing works
Self-citationQuality of life during the first 6 months of interferon-b treatment in patients with MS
Arnoldus, J. H. A., Killestein, J., Pfennings, L. E. M. A., Jelles, B., Uitdehaag, B. M. J., & Polman, C. H. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600508 · Cited by 62 · see citing works
McKay, K. A., Tremlett, H. L., Patten, S. B., Fisk, J. D., Evans, C. D., Fiest, K. M., Campbell, T. L., Marrie, R. A., & for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS) (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516657440 · Cited by 57 · see citing works
Vermersch, P., Hobart, J. C., Dive‐Pouletty, C., Bozzi, S., Hass, S., & Coyle, P. K. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516657441 · Cited by 57 · see citing works
Emerging oral therapies for multiple sclerosis
Cohen, B. A., & Rieckmann, P. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01561..x · Cited by 56 · see citing works
Giovannoni, G., Барбараш, О. Л., Casset‐Semanaz, F., Jaber, A., King, J. O., Metz, L. M., Pardo, G., Simsarian, J., Sørensen, P. S., & Stubinski, B. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.002 · Cited by 55 · see citing works
Turner, A. P., Sloan, A. P., Kivlahan, D. R., & Haselkorn, J. K. (2014) · Rehabilitation Psychology · doi:10.1037/a0036322 · Cited by 54 · see citing works
Lafata, J. E., Cerghet, M., Dobie, E., Schultz, L. R., Tunceli, K., & Reuther, J. (2008) · Journal of the American Pharmacists Association · doi:10.1331/japha.2008.07116 · Cited by 54 · see citing works
Diagnosis and Treatment of Major Depressive Disorder
Soleimani, L., Lapidus, K. A. B., & Iosifescu, D. V. (2010) · Neurologic Clinics · doi:10.1016/j.ncl.2010.10.010 · Cited by 51 · see citing works
Twork, S., Nippert, I., Scherer, P., Haas, J., Pöhlau, D., & Kügler, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x188125 · Cited by 53 · see citing works
Informed shared decision making in multiple sclerosis—inevitable or impossible?
Heesen, C., Kasper, J., Köpke, S., Richter, T., Segal, J., & Mühlhauser, I. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.05.074 · Cited by 52 · see citing works
Mohr, D. C., Cox, D., & Merluzzi, N. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1146oa · Cited by 51 · see citing works
Self-citationAdherence to interferon-beta treatment and results of therapy switching
Clerico, M., Barbero, P., Contessa, G., Ferrero, C., & Durelli, L. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.05.075 · Cited by 50 · see citing works
Kiropoulos, L. A., Kilpatrick, T., Holmes, A., & Threader, J. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1152-7 · Cited by 50 · see citing works
Factors Leading Patients to Discontinue Multiple Sclerosis Therapies
Daugherty, K. K., Butler, J. S., Mattingly, M., & Ryan, M. A. (2005) · Journal of the American Pharmacists Association · doi:10.1331/1544345054003804 · Cited by 49 · see citing works
Reen, G., Silber, E., & Langdon, D. W. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.12.038 · Cited by 49 · see citing works
Patient and community preferences for treatments and health states in multiple sclerosis
Prosser, L. A., Kuntz, K. M., Bar‐Or, A., & Weinstein, M. C. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms903oa · Cited by 48 · see citing works
Mohr, D. C., Goodkin, D. E., Masuoka, L. K., Dick, L. P., Russo, D. P., Eckhardt, J., Boudewyn, A. C., & Bedell, L. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500309 · Cited by 44 · see citing works
Self-citationWeb-based intervention support system for health promotion
Liang, H., Xue, Y., & Berger, B. A. (2005) · Decision Support Systems · doi:10.1016/j.dss.2005.02.001 · Cited by 41 · see citing works
Prosser, L. A., Kuntz, K. M., Bar‐Or, A., & Weinstein, M. C. (2002) · Medical Decision Making · doi:10.1177/0272989x02238299 · Cited by 40 · see citing works
cost sharing, benefit design, and adherence: The case of multiple sclerosis
Dor, A., Lage, M. J., Tarrants, M. L., & Castelli‐Haley, J. (2010) · Advances in health economics and health services research · doi:10.1108/s0731-2199(2010)0000022011 · Cited by 39 · see citing works
Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis
Hincapie, A. L., Penm, J. H.-D., & Burns, C. F. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.8.822 · Cited by 38 · see citing works
Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
Fernández, Ó., Agüera, J., Izquierdo, G., Millán-Pascual, J., Torrentà, L. R., Oliva, P., Argente, J., Montero, Y. E. B., Soler, J. M., Carmona, O., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035600 · Cited by 36 · see citing works
Disease-modifying drugs for multiple sclerosis: current and future aspects
Freedman, M. S. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.1.s1 · Cited by 33 · see citing works
Nelson, C. J., Hsiao, W., Balk, E., Narus, J., Tal, R., Bennett, N. E., & Mulhall, J. P. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12271 · Cited by 32 · see citing works
Ziemssen, T., Calabrese, P., Penner, I., & Apfel, R. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8058-7 · Cited by 31 · see citing works
Lessons from 10 years of interferon beta-1b (Betaferon�/Betaseron�) treatment
Bayas, A., & Gold, R. (2003) · Journal of Neurology · doi:10.1007/s00415-003-1402-8 · Cited by 29 · see citing works
Depression in Multiple Sclerosis Associated with Interferon Beta-1a (Rebif)
Pandya, R., & Patten, S. B. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700720 · Cited by 28 · see citing works
Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis
Cunningham, A., Gottberg, K., von Koch, L., & Hillert, J. A. (2010) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2009.01285.x · Cited by 27 · see citing works
The Evolving Role of the Multiple Sclerosis Nurse
Burke, T. V., Dishon, S., McEwan, L., & Smrtka, J. (2011) · International Journal of MS Care · doi:10.7224/1537-2073-13.3.105 · Cited by 27 · see citing works
Janssens, A. C. J. W., de Boer, J. B., van Doorn, P. A., van der Ploeg, H. M., van der Meché, F. G. A., Passchier, J., & Hintzen, R. Q. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00583.x · Cited by 27 · see citing works
Berger, B. A., Hudmon, K., & Liang, H.-G. (2004) · Journal of the American Pharmacists Association · doi:10.1331/1544345041475607 · Cited by 28 · see citing works
Kasper, J., van de Roemer, A., Pöttgen, J., Rahn, A. C., Backhus, I., Bay, Y., Köpke, S., & Heesen, C. (2016) · Health Expectations · doi:10.1111/hex.12522 · Cited by 26 · see citing works
The safety and efficacy of IFN-β products for the treatment of multiple sclerosis
Kremenchutzky, M., Morrow, S. A., & Rush, C. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.3.279 · Cited by 26 · see citing works
Battista, G. D., Bertolotto, A., Gasperini, C., Ghezzi, A., Maimone, D., & Solaro, C. M. (2014) · Multiple Sclerosis International · doi:10.1155/2014/752318 · Cited by 25 · see citing works
Moreau, T., Schmidt, N., Joyeux, O., Bungener, C., & Souvignet, V. (2009) · European Neurology · doi:10.1159/000222777 · Cited by 24 · see citing works
Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis
Visser, L. H., & van der Zande, A. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03411.x · Cited by 23 · see citing works
Soucy, N., Soucy, & Girouard (2011) · Patient Preference and Adherence · doi:10.2147/ppa.s10506 · Cited by 23 · see citing works
Working-age persons with multiple sclerosis and access to disease-modifying medications
Iezzoni, L. I., Ngo, L. H., & Kinkel, R. P. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458507080466 · Cited by 23 · see citing works
Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study
Minden, S. L., Hoaglin, D. C., Jureidini, S., Hadden, L. S., Frankel, D., Komatsuzaki, Y., & Outley, J. K. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458507086463 · Cited by 23 · see citing works
REVIEW OF INTERVENTION STUDIES ON DEPRESSION IN PERSONS WITH MULTIPLE SCLEROSIS
Walker, I., & Gonzalez, E. (2007) · Issues in Mental Health Nursing · doi:10.1080/01612840701344480 · Cited by 25 · see citing works
Halper, J., Centonze, D., Newsome, S. D., Huang, D., Robertson, C., You, X., Sabatella, G., Evilevitch, V., & Leahy, L. (2015) · International Journal of MS Care · doi:10.7224/1537-2073.2015-042 · Cited by 22 · see citing works
Health Promotion in People with Multiple Sclerosis
Bombardier, C. H., Wadhwani, R. V., & LaRotonda, C. J. (2005) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2005.01.002 · Cited by 21 · see citing works
Patient Perspectives on Disease-Modifying Therapy in Multiple Sclerosis
Johnson, K. L., Kuehn, C. M., Yorkston, K. M., Kraft, G. H., Klasner, E. R., & Amtmann, D. (2006) · International Journal of MS Care · doi:10.7224/1537-2073-8.1.11 · Cited by 20 · see citing works
Cox, D., & Mohr, D. C. (2003) · American Journal of Drug Delivery · doi:10.2165/00137696-200301030-00005 · Cited by 19 · see citing works
Self-citationFilipi, M. L., Beavin, J., Brillante, R. T., Costello, K., Hartley, G., Hartley, K., Namey, M., O’Leary, S., & Remington, G. M. (2014) · International Journal of MS Care · doi:10.7224/1537-2073.2013-006 · Cited by 18 · see citing works
Individualizing treatment goals and interventions for people with MS
Giovannoni, G., & Rhoades, R. W. (2012) · Current Opinion in Neurology · doi:10.1097/01.wco.0000413321.32834.aa · Cited by 18 · see citing works
Therapieadhärenz in der neurologischen Praxis
Kern, S., Reichmann, H., & Ziemssen, T. (2008) · Der Nervenarzt · doi:10.1007/s00115-008-2419-0 · Cited by 17 · see citing works
Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis
Zettl, U. K., Schreiber, H., Bauer-Steinhusen, U., Gläser, T., Hechenbichler, K., Hecker, M., & for the BETAPATH Study Group (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12705 · Cited by 16 · see citing works
Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany
Becker, V., Heeschen, V., Schuh, K., Schieb, H., & Ziemssen, T. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617748845 · Cited by 16 · see citing works
Parks, N. E., Andreou, P., Marrie, R. A., Fisk, J. D., Bhan, V., & Kirkland, S. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103249 · Cited by 15 · see citing works
Depression in Multiple Sclerosis: Reactive or Endogenous?
Holden, K. E., & Isaac, C. (2011) · Clinical Neuropsychologist · doi:10.1080/13854046.2011.564208 · Cited by 20 · see citing works
Clinically Isolated Syndrome and Early Relapsing Multiple Sclerosis
Metz, L. M. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000729 · Cited by 15 · see citing works
Enhancing Adherence Through Education
Smrtka, J., Caon, C., Saunders, C., Becker, B. L., & Baxter, N. N. (2010) · Journal of Neuroscience Nursing · doi:10.1097/jnn.0b013e3181ef82b6 · Cited by 14 · see citing works
Knowledge and attitude assessment of Iranian multiple sclerosis patients receiving interferon beta.
Abolfazli, R., Elyasi, A., Javadi, M. R., Gholami, K., Torkamandi, H., Amir-Shahkarami, M., Etemadifar, M., & Nasr, Z. (2014) · Europe PMC (PubMed Central) · Cited by 14 · see citing works
Heesen, C., Pöttgen, J., Rahn, A. C., Liethmann, K., Kasper, J., Vahter, L., Drulovic, J. S., van Nunen, A., Wilkie, D., Beckmann, Y. Y., et al. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.09.020 · Cited by 14 · see citing works
Psychological interventions for multiple sclerosis
Thomas, P., Thomas, S., Hillier, C., Galvin, K., Baker, R. D., & Cole, J. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004431 · Cited by 14 · see citing works
Pharmaceutical Industry discursives and the marketization of nursing work: a case example
Springer, R. A. (2011) · Nursing Philosophy · doi:10.1111/j.1466-769x.2011.00498.x · Cited by 13 · see citing works
Yamout, B., Dahdaleh, M. P., Jumah, M. A. A., Al-Shammri, S., Sharoqi, I. A., Tahan, A. A., Bohlega, S., Deleu, D., Inshasi, J. S. S., Khalifa, A., et al. (2010) · International Journal of Neuroscience · doi:10.3109/00207450903541087 · Cited by 12 · see citing works
Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool
Col, N. F., Solomon, A. J., Álvarez, E., Pbert, L. A., Ionete, C., Morales, I. B., Chester, J. G., Kutz, C. F., Iwuchukwu, C., Livingston, T., et al. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.105092 · Cited by 11 · see citing works
Best Practices in Multiple Sclerosis
Namey, M., Halper, J., O’Leary, S., Beavin, J., & Bishop, C. (2010) · Journal of Infusion Nursing · doi:10.1097/nan.0b013e3181cfd36d · Cited by 11 · see citing works
Reen, G., Silber, E., & Langdon, D. W. (2016) · Patient Education and Counseling · doi:10.1016/j.pec.2016.12.028 · Cited by 11 · see citing works
Treatment discontinuation in multiple sclerosis: The French Web-based survey ALLIANCE
Donzé, C., Malapel, L., Kwiatkowski, A., Lenne, B., Louchard, P., Neuville, V., & Hautecœur, P. (2015) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217315600720 · Cited by 10 · see citing works
Col, N. F., Álvarez, E., Springmann, V., Ionete, C., Morales, I. B., Solomon, A. J., Kutz, C. F., Griffin, C., Tierman, B., Livingston, T., et al. (2019) · MDM Policy & Practice · doi:10.1177/2381468319879134 · Cited by 9 · see citing works
Self-citationAcceptance of the Extracare Program by Beta Interferon-Treated Patients With Multiple Sclerosis
Freidel, M., Ortler, S., Fuchs, A., Seibert, S., & Schuh, K. (2014) · Journal of Neuroscience Nursing · doi:10.1097/jnn.0000000000000100 · Cited by 9 · see citing works
Kiropoulos, L., Kilpatrick, T., Kalincek, T., Cherulov, L., Mcdonald, E., Wijeratne, T., Threader, J., Rozenblat, V., Simpson-O’Brien, N., van der Walt, A., et al. (2020) · Trials · doi:10.1186/s13063-019-4018-8 · Cited by 8 · see citing works
Treatment adherence: what is the best that can be achieved?
Hutchinson, M. (2005) · PubMed · Cited by 8 · see citing works
Comparative evaluation of patients’ and physicians’ satisfaction with interferon beta-1b therapy
for the Study Group, Zettl, U. K., Bauer-Steinhusen, U., Gläser, T., Hechenbichler, K., & Hecker, M. (2016) · BMC Neurology · doi:10.1186/s12883-016-0705-1 · Cited by 7 · see citing works
- Authors
- Mohr, D. C., Goodkin, D. E., Likosk, W., Gatto, N., Neilley, L. K., Griffin, C., & Stiebling, B.
- Affiliations
- University of California, San Francisco (US)
- Kaiser Permanente (US)
- Cleveland Clinic (US)
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 1996-12
- Volume
- 2
- Issue
- 5
- Pages
- 222-226
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W1563651942
- Cited by
- 131
- References
- 9
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 13 · 2015: 3 · 2014: 6 · 2013: 2 · 2012: 7
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Multiple Sclerosis Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Health Professions › General Health Professions › Patient-Provider Communication in Healthcare
- Keywords
- multiple sclerosis, interferon beta-1b, treatment expectations, medication adherence, patient education, treatment discontinuation, attack rate, functional status, adverse effects, depression, flu-like symptoms
- MeSH terms
- Interferon beta-1a, Interferon beta-1b, Adjuvants, Immunologic, Attitude to Health, Female, Humans, Male, Multiple Sclerosis, Patient Compliance, Patient Dropouts, Patient Education as Topic, Interferon-beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
